
BBOT Stock Forecast & Price Target
BBOT Analyst Ratings
Bulls say
BridgeBio Oncology is well positioned for success due to their focus on addressing KRAS and PI3Kα oncogenes in cancer, with promising inhibitors and potential best-in-class treatments. Their strong financial position and addition of an experienced executive also bode well for the company's potential for success in the oncology market.
Bears say
BridgeBio Oncology is facing numerous risks and challenges that could significantly impact their future and target price. Some of these include safety concerns, regulatory hurdles, and intense competition in the KRAS G12C inhibitor class that has already set a low efficacy and safety bar with little clinically meaningful benefit. Additionally, the company's novel approach to selectively targeting PI3Kα while sparing glucose homeostasis may not translate to significant clinical benefits, and their monotherapy and combination trials in different cancer types are still early and require further validation.
This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBOT Analyst Forecast & Price Prediction
Start investing in BBOT
Order type
Buy in
Order amount
Est. shares
0 shares